Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis

The American Journal of Gastroenterology
Geert D'HaensPaul Streck

Abstract

Treatment with mesalamine to maintain endoscopic remission (mucosal healing) of ulcerative colitis (UC) has been shown to reduce the risk of relapse and is the recommended first-line maintenance therapy. To improve treatment adherence, a mesalamine formulation that can be administered once-daily, MMX(®) mesalamine (Lialda; Shire Pharmaceuticals LLC, Wayne, PA), was developed. This study was conducted to determine the efficacy and safety of once-daily MMX mesalamine compared with twice-daily delayed-release mesalamine (Asacol; Warner Chilcott, Dublin, Ireland) for maintaining endoscopic remission in patients with UC. A multicenter, randomized, double-blind, 6-month, active-control trial was conducted to assess the non-inferiority of once-daily MMX mesalamine 2.4 g/day compared with twice-daily delayed-release mesalamine at a total daily dose of 1.6 g/day in patients with UC in endoscopic remission. The primary end point was maintenance of endoscopic remission at month 6 in the per-protocol (PP) population. Overall, 826 patients were randomized and dosed. The primary objective (non-inferiority) was met. At month 6, 83.7 and 77.8% of patients receiving MMX mesalamine in the PP and intent-to-treat (ITT) populations, respectively, h...Continue Reading

References

Dec 24, 1987·The New England Journal of Medicine·K W SchroederD M Ilstrup
Oct 1, 1993·Digestive Diseases and Sciences·J P WrightK Jaskiewicz
Jul 19, 2002·Gastroenterology Clinics of North America·Edward V Loftus, William J Sandborn
Apr 28, 2006·Statistics in Medicine·UNKNOWN Committee for Medicinal Products for Human UseUNKNOWN Committee for Release for Consultation
Jan 20, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Gary R LichtensteinWilliam J Sandborn
Jan 24, 2007·Gastroenterology·Michael A KammRaymond E Joseph
Aug 8, 2007·Gastroenterology·Kathrine Frey FrøslieUNKNOWN IBSEN Group
Jul 29, 2009·Inflammatory Bowel Diseases·Gary R Lichtenstein, Paul Rutgeerts
Jan 14, 2010·The American Journal of Gastroenterology·Asher KornbluthUNKNOWN Practice Parameters Committee of the American College of Gastroenterology
Feb 16, 2010·Digestive Diseases and Sciences·David T RubinJoseph Hopper
Dec 9, 2010·Alimentary Pharmacology & Therapeutics·W KruisUNKNOWN International Salofalk OD Study Group
Mar 1, 2008·Journal of Crohn's & Colitis·S P L TravisUNKNOWN European Crohn's and Colitis Organisation (ECCO)

❮ Previous
Next ❯

Citations

Feb 26, 2016·Journal of Crohn's & Colitis·David T RubinUNKNOWN Ulcerative Colitis Remission Study Group
Sep 14, 2012·Expert Opinion on Pharmacotherapy·Sara N Horst, Sunanda Kane
May 18, 2017·Journal of Crohn's & Colitis·Marcus HarbordUNKNOWN European Crohn’s and Colitis Organisation [ECCO]
Nov 6, 2015·Inflammatory Bowel Diseases·Nilesh ChandeBrian G Feagan
May 4, 2018·Alimentary Pharmacology & Therapeutics·P SehgalN Narula
Nov 7, 2015·Digestive Diseases and Sciences·Gary R Lichtenstein
Oct 5, 2018·Expert Review of Gastroenterology & Hepatology·Belinda Jackson, Peter De Cruz
May 4, 2013·Expert Review of Gastroenterology & Hepatology·Makoto NaganumaToshifumi Hibi
Apr 12, 2014·Paediatric Drugs·Brian P Regan, Athos Bousvaros
May 10, 2016·The Cochrane Database of Systematic Reviews·Yongjun WangJohn K MacDonald
Mar 18, 2020·Journal of Crohn's & Colitis·Stefan SchreiberKaren Barrett
Mar 22, 2014·Expert Review of Gastroenterology & Hepatology·Anthony O'Connor, Alan C Moss
May 9, 2015·Advances in Therapy·Adeyinka Abinusawa, Srini Tenjarla
Aug 29, 2020·The Cochrane Database of Systematic Reviews·Alistair MurrayJohn K MacDonald
May 24, 2016·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·Wei LiXue-Liang Jiang
Sep 25, 2012·Gastroenterology·Geert D'HaensUNKNOWN International Organization for Inflammatory Bowel Diseases (IOIBD) and the Clinical Trial Committee Clincom of the European

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.